-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HCV-IN-33
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2757963-83-8.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 2757963-83-8 |
| Description | HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor. |
Product Information
| Synonyms | HCV-IN-33|HY-144106|CS-0376497 |
| Molecular Weight | 514.1 |
| Molecular Formula | C31H36ClN5 |
| Canonical SMILES | CN1CCCN(CC1)C2=CC(=C(C=C2)C#N)CN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=C(C=C5)Cl |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 731 |
| Exact Mass | 513.2659239 |
| Target | HCV |
| XLogP3-AA | 5.4 |
